NEWS

Acandis GmbH Announces Start of Patient Recruitment for CARESTAR Study i...

Acandis GmbH, a leading German-based medical technology company specialising in medical devices for the treatment of neurovascular diseases, today announced the start of patient recruitment for the CARESTAR study following final positive approval from the responsible Ethics Committee. The study is registered on ClinicalTrials.gov (Identifier: NCT07166731).

Thank you for your submission

M2 thrombectomy in a 91-year-old: decision-making in a high‑risk patient

Spinal perimedullary AVM: an advanced transvenous approach

Day 2 at LINNC Americas - Innovation Across Aneurysm, Stroke, AV Shunts, and Pediatric Neurointervention

Day 1 at LINNC Americas 2026: Live from Orlando

Access the streaming

ICA-M1 intracranial dissection EVT

Vesalio Expands International Neurovascular Portfolio with CE Mark of Ne...

Vesalio, a global leader in vascular intervention, today announced CE Mark certification and the European commercial launch of two new neurovascular devices: NeVa™ VS, for the treatment of cerebral vasospasm following aneurysmal subarachnoid hemorrhage (aSAH), and the NeVa™ 3.0 mm Thrombectomy System for stroke. In addition, the Company received an additional U.S. Food and Drug Administration (FDA) 510(k) clearance expanding the indications of its neurovascular and peripheral aspiration catheters to include distal access.Plano, Texas – February 10, 2026

Rapid Medical™’s DISTALS Trial Overwhelmingly Positive, Demonstrating Su...

TIGERTRIEVER™ 13 is the first device shown to meet safety and effectiveness endpoints for restoring blood flow in smaller but critical areas of the brain, accounting for almost 50% of all ischemic strokesNEW ORLEANS & YOKNEAM, Israel--( BUSINESS WIRE )-- Rapid Medical™ , a leading developer of active endovascular devices, today announced late-breaking results from the DISTALS multicenter, randomized controlled trial showing that TIGERTRIEVER™ 13 achieved superior brain tissue reperfusion with an excellent safety profile when compared with medical management in medium vessel occlusion (MVO) stroke. The findings were presented in the main closing session at the 2026 International Stroke Conference (ISC) .